Loading
A phase 3 trial in lung cancer, run by Dr Arvindran A/L Alaga, now recruiting.
Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC is a phase 3, randomised interventional study registered as NCT07050043 by Dr Arvindran A/L Alaga, with a registry enrolment figure of 123 participants, started 2025-05-19 and due to reach its primary completion in 2030-12-31. Interventions recorded: Nivolumab 40mg; Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Docetaxel. Conditions listed: NSCLC (Non-small Cell Lung Carcinoma); First Line Therapy; Locally Advanced/Metastatic NSCLC. Primary outcome: Progression Free Survival (PFS). Lung eligibility wording from the registry: "Histologically confirmed, treatment naïve, locally advanced, or metastatic (stage IIIB - IV (per AJCC version 8), squamous or non-squamous NSCLC with documented PD-L1 expression and is not eligible for definitive chemo-radiation curative therapy and surgery". Sites: Malaysia. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Non-small-cell lung cancer and the tag lung-deep-dive.